- Home
- BMEA vs INVE Comparison
BMEA vs INVE Comparison
Compare BMEA & INVE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BMEA
- INVE
- Stock Information
- Founded
- BMEA 2017
- INVE 1990
- Country
- BMEA United States
- INVE United States
- Employees
- BMEA N/A
- INVE N/A
- Industry
- BMEA Biotechnology: Pharmaceutical Preparations
- INVE Computer peripheral equipment
- Sector
- BMEA Health Care
- INVE Technology
- Exchange
- BMEA Nasdaq
- INVE Nasdaq
- Market Cap
- BMEA 65.8M
- INVE 82.7M
- IPO Year
- BMEA 2021
- INVE 1997
- Fundamental
- Price
- BMEA $1.71
- INVE $3.49
- Analyst Decision
- BMEA Strong Buy
- INVE Strong Buy
- Analyst Count
- BMEA 10
- INVE 3
- Target Price
- BMEA $21.00
- INVE $6.50
- AVG Volume (30 Days)
- BMEA 1.1M
- INVE 87.1K
- Earning Date
- BMEA 08-04-2025
- INVE 08-07-2025
- Dividend Yield
- BMEA N/A
- INVE N/A
- EPS Growth
- BMEA N/A
- INVE N/A
- EPS
- BMEA N/A
- INVE 3.12
- Revenue
- BMEA N/A
- INVE $25,239,000.00
- Revenue This Year
- BMEA N/A
- INVE N/A
- Revenue Next Year
- BMEA N/A
- INVE $9.00
- P/E Ratio
- BMEA N/A
- INVE $1.13
- Revenue Growth
- BMEA N/A
- INVE N/A
- 52 Week Low
- BMEA $1.29
- INVE $2.86
- 52 Week High
- BMEA $13.07
- INVE $4.29
- Technical
- Relative Strength Index (RSI)
- BMEA 41.35
- INVE 53.77
- Support Level
- BMEA $1.65
- INVE $3.33
- Resistance Level
- BMEA $1.85
- INVE $3.64
- Average True Range (ATR)
- BMEA 0.11
- INVE 0.15
- MACD
- BMEA -0.01
- INVE 0.02
- Stochastic Oscillator
- BMEA 5.56
- INVE 43.48
About BMEA Biomea Fusion Inc.
Biomea Fusion Inc is a clinical-stage diabetes and obesity medicines company focused on the discovery and development of oral covalent small-molecule drugs to treat patients with metabolic diseases. The company uses its proprietary FUSION System discovery platform to develop a pipeline of novel small-molecule product candidates. Its principal clinical program's drug candidate, icovamenib, is being developed as an orally bioavailable, selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity. The company is also developing BMF-650, an investigational, oral small-molecule GLP-1 RA, which has the potential to be a therapeutic option for diabetes and obesity.
About INVE Identiv Inc.
Identiv Inc is a security technology company. It secures and manages access to physical places, things, and information. The company has one reportable segment: the IoT Business segment. Geographically, it generates maximum revenue from the Americas and also has a presence in Europe and the Middle East, and Asia-Pacific.